Phaseline

Targets › GABRA2

GABRA2 (Gamma-aminobutyric acid receptor subunit alpha-2): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Psychiatry, Gastroenterology; next expected readout Apr 2027.

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain. GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interfaces (By similarity). (UniProt, P47869)

Open in Phaseline: the race on GABRA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Xi'an Aerospace General HospitalCiprofol
GABA-A receptor positive allosteric modulator
GABRA1, GABRA2, GABRA3Phase 4Cholelithiasis–
University of California, Los AngelesIntravenous Alcohol (6% ethanol v/v in saline)
GABA-A receptor positive allosteric modulator; CNS depressant
GABRA1, GABRA2, GABRA3Phase 2Alcohol Use DisorderApr 2027

Conditions

Alcohol Use Disorder (1) Cholelithiasis (1)

Modalities

small molecule (2)

Companies

University of California, Los Angeles (1) Xi'an Aerospace General Hospital (1)

Related targets

GABRA1 (2) GABRA3 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.